New White Paper
BEYOND THE BELL CURVE: Unearthing rare and hard-to-treat disease information in the GenAI era.
As AI becomes a ubiquitous source of health answers, what happens to the people who aren’t typical cases?
Explore the reportExecutive Summary
AI knows what’s likely. How about what’s rare?
GenAI is rapidly becoming an intermediary between people and health information. For rare and hard-to-treat diseases, that creates extraordinary opportunity and disproportionate risk.
Patients
Bring lived experience and real-world insight that enriches AI answers.
Clinicians
Provide clinical context, guidance, and validation that help separate signal from noise.
Pharma
Contributes trusted information and expertise to help close knowledge gaps for rare and hard-to-treat diseases.
This white paper explores how patients, clinicians, and pharma all have a role in making the information ecosystem safer and more useful. And it posits that the future of healthcare information isn’t human or AI. It is humans learning how to make AI better informed—and AI helping humans navigate what no individual could know alone.
4/5
physicians report professional AI use4
AI usage by physicians has doubled since 2023
Source: AMA
1/5
people who use AI to get information about rare diseases discuss the findings with a clinician.
Source: JMIR, 2026
Download PDF
Access the full report.
Provide a few details about yourself to immediately unlock your download link for "Beyond the Bell Curve: Unearthing rare and hard-to-treat disease information in the GenAI era."
We respect your privacy. See our Privacy Policy
Related Perspectives
Explore more topics on AI, rare disease, and healthcare communications.
24/364 Brings Rare Disease Stories into the Spotlight With Inaugural Film Festival
The inaugural 24/364 Rare Disease Film Festival will bring patients, caregivers, advocates, filmmakers, and healthcare leaders together in San Diego in March 2027 to share the human stories behind rare disease. Sponsored by CG Life, the festival will feature screenings, filmmaker conversations, and panel discussions that invite audiences to better understand lives and experiences too often unseen. It embodies the purpose behind 24/364: creating awareness, connection, and action through stories that deserve attention every day of the year. We look forward to celebrating the people bringing these stories to light.
CG Life and The Considered Celebrate Four Honors at the 2026 MM+M Awards
CG Life and The Considered have been recognized with four honors at the 2026 MM+M Awards, celebrating the people, partnerships, and ideas behind our work. CG Life earned Silver for Rare Disease Agency of the Year, while The Considered was named Boutique Agency of the Year. Jay Carter received the David Gideon Leadership Award, and the NovoMedLink redesign for Novo Nordisk earned Silver for Branded Website for Healthcare Professionals. Together, these honors reflect a shared commitment to bringing scientific understanding, creativity, and care to healthcare communications. We’re proud of our teams and grateful to the clients and partners who make this work possible.
CG Life Releases “Dylan Findling,” the Second Film in the 24/364 “In the Light” Series
Dylan Findling has debuted as the second installment of “In the Light,” a series from 24/364, an initiative created by CG Life to keep a light on rare disease year-round. The intimate short documentary follows Dylan and his family as they find connection and hope following his diagnosis of adrenoleukodystrophy (ALD) at age nine. Through school, art, basketball, and the everyday moments that bring them together, the Findlings share a story of love and life beyond a diagnosis. We hope you’ll take time to experience their journey and get to know the people at its heart.